QPharma Appoints Chief Medical Officer
News May 17, 2013
In addition to his training as a physician, Dr. Shaw is a highly experienced business executive and entrepreneur. He previously served as President and Chief Operating Officer of MD Mindset, LLC, a leading pharma sales force and marketing effectiveness firm, with day-to-day responsibility for company operations, product development, and business development. Prior to this, he was the President and founder of London-based Metamorph Doctors, Inc., which was established to train medical sales professionals to communicate with physicians more effectively. After earning his medical degree from Charing Cross Hospital Medical School at the University of London, Dr. Shaw spent many years practicing medicine across various specialties at hospitals in the United Kingdom.
“I’m thrilled to be joining QPharma, which has a deserved reputation as a leader in providing compliance and brand services to the highly regulated pharmaceutical, medical device, and other life sciences industries,” said Dr. Shaw, who has worked with numerous international pharmaceutical firms as an advisory board member. “The company continues to enjoy strong and consistent growth, and I look forward to playing a role in furthering its successes.”
“Dr. Shaw’s breadth of experience as a physician, executive, and respected key opinion leader in the pharmaceutical industry speaks for itself,” said QPharma President and CEO Patrick P. Den Boer. “I am confident that he will bring outstanding value to our clients as a core member of our executive leadership team.”
A new type of opioid doesn’t have the side effects (such as increased pain sensitivity or and increased risk of chronic pain) associated with morphine and other opioid-based painkillers, and accelerates recovery time from pain compared to morphine, according to a new preclinical study.READ MORE
The Alzheimer drug candidate PRI-002 has successfully completed Phase I of clinical research involving healthy volunteers. When administered daily over a period of four weeks, the active substance proved to be safe for use in humans. The next milestone will be the proof of efficacy in patients in clinical Phase II.READ MORE